



**WHO International Standard  
2nd International Standard for Granulocyte Colony Stimulating  
Factor (Human rDNA derived)  
NIBSC code: 09/136  
Instructions for use  
(Version 2.0, Dated 12/04/2013)**

### 1. INTENDED USE

The preparation coded 09/136 was established as the 2<sup>nd</sup> International Standard for Granulocyte Colony Stimulating Factor (G-CSF) following evaluation in an international collaborative study. This 2<sup>nd</sup> International Standard is the primary biological standard for Granulocyte Colony Stimulating Factor and replaces the 1<sup>st</sup> International Standard for Granulocyte Colony Stimulating Factor coded 88/502.

### 2. CAUTION

**This preparation is not for administration to humans or animals in the human food chain.**

The preparation contains material of human origin, and either the final product or the source materials, from which it is derived, have been tested and found negative for HBsAg, anti-HIV and HCV RNA. As with all materials of biological origin, this preparation should be regarded as potentially hazardous to health. It should be used and discarded according to your own laboratory's safety procedures. Such safety procedures should include the wearing of protective gloves and avoiding the generation of aerosols. Care should be exercised in opening ampoules or vials, to avoid cuts.

### 3. UNITAGE

The assigned potency agreed on the basis of an International Collaborative Study is 95,000 International Units of biological activity per ampoule. The biological potency of 09/136 was derived relative to the 1<sup>st</sup> International Standard for Granulocyte Colony Stimulating Factor coded 88/502.

### 4. CONTENTS

Country of origin of biological material: United Kingdom.  
Each ampoule contains the residue after freeze-drying of 1.0 ml of a solution comprising:

G-CSF, approximately 1000 ng  
10 mg L-Arginine  
10 mg L-Phenylalanine  
5 mg Trehalose  
2 mg Human Serum Albumin  
0.01 % Tween 20

The G-CSF protein was expressed in E.coli.

### 5. STORAGE

For economy of use, it is recommended that the solution be sub divided into several small aliquots and stored at -40°C or below. Avoid repeated thawing/freezing. Unopened ampoules should be stored at -20°C.

**Please note: because of the inherent stability of lyophilized material, NIBSC may ship these materials at ambient temperature.**

### 6. DIRECTIONS FOR OPENING

DIN ampoules have an 'easy-open' coloured stress point, where the narrow ampoule stem joins the wider ampoule body. Various types of ampoule breaker are available commercially. To open the ampoule, tap the ampoule gently to collect material at the bottom (labelled) end and follow manufactures instructions provided with the ampoule breaker.

### 7. USE OF MATERIAL

**No attempt should be made to weigh out any portion of the freeze-dried material prior to reconstitution**

Dissolve the total contents of the ampoule in 1.0ml of sterile distilled water. This solution will contain G-CSF at a concentration of 95,000 International Units/ml. Use carrier protein where extensive dilution is required.

### 8. STABILITY

Reference materials are held at NIBSC within assured, temperature-controlled storage facilities and they should be stored on receipt as indicated on the label. It is the policy of WHO not to assign an expiry date to their international reference materials. Accelerated degradation studies have indicated that this material is suitably stable, when stored at -20°C or below, for the assigned values to remain valid until the material is withdrawn or replaced. These studies have also shown that the material is suitably stable for shipment at ambient temperature without any effect on the assigned values. Once reconstituted, diluted or aliquoted, users should determine the stability of the material according to their own method of preparation, storage and use. Users who have data supporting any deterioration in the characteristics of any reference preparation are encouraged to contact NIBSC.

### 9. REFERENCES

This standard was produced under WHO guidelines cited in the WHO Technical Reports Series, No. 932, 2006, Annex 2.  
Report on a Collaborative study for proposed 2<sup>nd</sup> International standard for Granulocyte colony stimulating factor (G-CSF) WHO/BS/10.2133  
[http://www.who.int/biologicals/expert\\_committee/BS\\_2133\\_2ndISGCSF190710-Final.pdf](http://www.who.int/biologicals/expert_committee/BS_2133_2ndISGCSF190710-Final.pdf)

### 10. ACKNOWLEDGEMENTS

We are thankful to several manufacturers for their generous donations of G-CSF preparations used in the collaborative study, and to the study participants for their contributions in evaluating the preparations.

### 11. FURTHER INFORMATION

Further information can be obtained as follows;  
This material: [enquiries@nibsc.org](mailto:enquiries@nibsc.org)  
WHO Biological Standards:  
<http://www.who.int/biologicals/en/>  
JCTLM Higher order reference materials:  
<http://www.bipm.org/en/committees/jc/jctlm/>  
Derivation of International Units:  
[http://www.nibsc.org/standardisation/international\\_standards.aspx](http://www.nibsc.org/standardisation/international_standards.aspx)  
Ordering standards from NIBSC:  
<http://www.nibsc.org/products/ordering.aspx>  
NIBSC Terms & Conditions:  
[http://www.nibsc.org/terms\\_and\\_conditions.aspx](http://www.nibsc.org/terms_and_conditions.aspx)

### 12. CUSTOMER FEEDBACK

Customers are encouraged to provide feedback on the suitability or use of the material provided or other aspects of our service. Please send any comments to [enquiries@nibsc.org](mailto:enquiries@nibsc.org)

### 13. CITATION

In all publications, including data sheets, in which this material is referenced, it is important that the preparation's title, its status, the NIBSC code number, and the name and address of NIBSC are cited and cited correctly.

### 14. MATERIAL SAFETY SHEET

Recommendations for the preparation, characterization and establishment of international and other biological reference standards [http://www.who.int/bloodproducts/publications/TRS932Annex2\\_Inter\\_biol\\_efstandardsrev2004.pdf](http://www.who.int/bloodproducts/publications/TRS932Annex2_Inter_biol_efstandardsrev2004.pdf) (revised 2004). They are officially endorsed by the WHO Expert Committee on Biological Standardization (ECBS) based on the report of the international collaborative study which established their suitability for the intended use.

Physical and Chemical properties	
<b>Classification in accordance with Directive 2000/54/EC, Regulation (EC) No 1272/2008:</b> <b>Not applicable or not</b> Physical appearance: Freeze dried powder	Corrosive: No
Stable: Yes	Oxidising: No
Hygroscopic: No	Irritant: No
Flammable: No	Handling: See caution, Section 2
Other (specify):	Contains material of human origin
Toxicological properties	
Effects of inhalation:	Not established, avoid inhalation
Effects of ingestion:	Not established, avoid ingestion
Effects of skin absorption:	Not established, avoid contact with skin
Suggested First Aid	
Inhalation:	Seek medical advice
Ingestion:	Seek medical advice
Contact with eyes:	Wash with copious amounts of water. Seek medical advice
Contact with skin:	Wash thoroughly with water.
Action on Spillage and Method of Disposal	
Spillage of ampoule contents should be taken up with absorbent material wetted with an appropriate disinfectant. Rinse area with an appropriate disinfectant followed by water. Absorbent materials used to treat spillage should be treated as biological waste.	

#### 15. LIABILITY AND LOSS

In the event that this document is translated into another language, the English language version shall prevail in the event of any inconsistencies between the documents.

Unless expressly stated otherwise by NIBSC, NIBSC's Standard Terms and Conditions for the Supply of Materials (available at [http://www.nibsc.org/About\\_Us/Terms\\_and\\_Conditions.aspx](http://www.nibsc.org/About_Us/Terms_and_Conditions.aspx) or upon request by the Recipient) ("Conditions") apply to the exclusion of all other terms and are hereby incorporated into this document by reference. The Recipient's attention is drawn in particular to the provisions of clause 11 of the Conditions.

#### 16. INFORMATION FOR CUSTOMS USE ONLY

<b>Country of origin for customs purposes*:</b> United Kingdom * Defined as the country where the goods have been produced and/or sufficiently processed to be classed as originating from the country of supply, for example a change of state such as freeze-drying.
<b>Net weight:</b> 4.6g
<b>Toxicity Statement:</b> Toxicity not assessed
<b>Veterinary certificate or other statement</b> if applicable. <b>Attached:</b> No

#### 17. CERTIFICATE OF ANALYSIS

NIBSC does not provide a Certificate of Analysis for WHO Biological Reference Materials because they are internationally recognised primary reference materials fully described in the instructions for use. The reference materials are established according to the WHO